Gilead Sciences (NASDAQ:GILD) Stock: Insider Daniel Patrick O’day Sells 15,000 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel O’Day sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $169.74, for a total transaction of $2,546,100.00. Following the sale, the chief executive officer owned 551,683 shares of the company’s stock, valued at approximately $93,642,672.42. This represents a 2.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Friday, October 30th, Daniel O’Day sold 15,881 shares of Gilead Sciences stock. The shares were sold at an average price of $175.25, for a total transaction of $2,783,145.25.
• On Thursday, October 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $147.90, for a total transaction of $2,218,500.00.
• On Tuesday, September 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $148.64, for a total transaction of $2,229,600.00.

Gilead Sciences Price Performance

Shares of GILD stock opened at $167.47 on Wednesday. The firm’s 50 day moving average price is $151.77 and its two-hundred day moving average price is $140.25. The company has a debt-to-equity ratio of 1.84, a quick ratio of 0.95 and a current ratio of 1.38. Gilead Sciences, Inc. has a 52-week low of $116.88 and a 52-week high of $175.65. The stock has a market cap of $207.72 billion, a PE ratio of -53.00 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.19 by $0.36. The company had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The business’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.47 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post -1.03 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. Gilead Sciences’s payout ratio is -103.80%.

Institutional Investors Weigh In On Gilead Sciences

Several institutional investors have recently bought and sold shares of GILD. Bank of Nova Scotia bought a new position in Gilead Sciences in the second quarter valued at $100,056,000. OMERS ADMINISTRATION Corp acquired a new stake in Gilead Sciences in the 2nd quarter valued at $55,754,000. Groupe la Francaise lifted its position in Gilead Sciences by 30.9% during the 2nd quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock worth $6,270,000 after buying an additional 11,712 shares in the last quarter. Baird Financial Group Inc. lifted its position in Gilead Sciences by 3.6% during the 2nd quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock worth $36,929,000 after buying an additional 10,206 shares in the last quarter. Finally, Headlands Technologies LLC bought a new stake in Gilead Sciences during the 2nd quarter worth about $6,251,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts remain broadly upbeat, with several recent price-target increases, including targets as high as $200. Coverage cites Gilead’s recent execution, HIV franchise and pipeline; a separate estimate of fair value also moved higher. Gilead price target raised to $200 Gilead fair-value estimate
• Positive Sentiment: Gilead plans to present results from more than 50 studies, including late-breaking clinical data and real-world evidence, at HIV Glasgow 2026 on November 8–11. The updates could offer pipeline and franchise catalysts. Gilead HIV Glasgow presentation
• Positive Sentiment: BioNTech said it advanced a planned Phase 3 trial, pending regulatory approval, combining its candidate pumitamig with Gilead’s cancer drug Trodelvy in triple-negative breast cancer. This represents potential progress for Gilead’s oncology collaboration, though the study remains subject to approval. BioNTech quarterly results and update
• Negative Sentiment: Investors bought 16,499 GILD put options, about 107% above typical volume. The jump may signal increased hedging or bearish positioning, although options activity alone does not establish a market view.
• Negative Sentiment: CEO Daniel O’Day sold a combined 30,881 shares in two recent transactions. Both sales were made under a prearranged Rule 10b5-1 plan, which may temper their significance, but insider selling can still be viewed cautiously by investors. CEO share sale details

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GILD. BMO Capital Markets restated an “outperform” rating and set a $184.00 target price on shares of Gilead Sciences in a report on Friday. Royal Bank Of Canada boosted their target price on Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a research report on Friday, October 30th. Citigroup upped their price target on Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Wells Fargo & Company increased their price target on shares of Gilead Sciences from $165.00 to $190.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Finally, Cantor Fitzgerald lifted their price objective on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Twenty-three analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $169.74.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.